Abstracts tagged "Infection"

Abstract Number: 736 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster and Disseminated Zoster in Systemic Lupus Erythematosus and Lupus Nephritis: Incidence Rates in Real-World Claims Data
Katherine Belendiuk¹, Yingjie Ding², Devika Chawla¹ and Matthew Cascino¹, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, Hoboken, NJ
Background/Purpose: Disseminated zoster is a highly morbid complication of varicella zoster reactivation (herpes zoster) that is typically associated with immunosuppression. Systemic lupus erythematosus (SLE) and…
Abstract Number: 1561 • 2018 ACR/ARHP Annual Meeting
B Lymphocyte Depletion Therapy with Rituximab in Primary Sjögren’s Syndrome: Indications , Effectiveness and Ultrasonographic Response
Francesco Ferro, Nicoletta Luciano, Elena Elefante, Maurizio Mazzantini, Marta Mosca and Chiara Baldini, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Aim of this study was to assess indications, effectiveness, clinical and ultrasonographic response to rituximab (RTX) therapy in primary Sjögren’s syndrome (pSS), focusing in…
Abstract Number: 745 • 2018 ACR/ARHP Annual Meeting
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: A Multi-Center Cohort Study from China
Ziqian Wang¹, Jiuliang ZHAO², Yanhong Wang³, Mengtao Li⁴ and Xiaofeng Zeng⁵, ¹Peking Union Medical College Hospital, China, Beijing, China, ²Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, ³Department of Epidemiology and Bio-statistics (YW), Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Rheumatology, Peking Union Medical College and Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: a Multi-center Cohort Study from ChinaZiqian Wang1, Jiuliang Zhao1, Yanhong…
Abstract Number: 1611 • 2018 ACR/ARHP Annual Meeting
Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
Paras Karmacharya¹, Cynthia S. Crowson², Dilli Poudel³, Pragya Shrestha⁴ and Kerry Wright⁵, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ⁴Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Increased risk of infections has been recognized in patients with psoriatic arthritis (PsA) compared to those without PsA. Immunomodulatory effects of PsA, immunosuppressive therapies…
Abstract Number: 769 • 2018 ACR/ARHP Annual Meeting
Herpes Zoster in Systemic Lupus Erythematosus: Prevalence and Risk Factors
Hanan Al Rayes¹, Nicole Anderson², Dennisse Bonilla², Jiandong Su² and Zahi Touma², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Herpes zoster (HZ) commonly observed in the elderly and in immune-compromised patients. The prevalence of HZ is 3.6-19.9% in previously reported data. The higher…
Abstract Number: 1883 • 2018 ACR/ARHP Annual Meeting
Infections Are Associated With Increased Risk of Giant Cell Arteritis – a Population-Based Case-Control Study From Southern Sweden
Pavlos Stamatis¹, Aleksandra Turkiewicz², Martin Englund², Goran Jönsson³, Jan-Åke Nilsson⁴, Carl Turesson⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ³Clinical Sciences Lund, Department of Infection Medicine, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁶Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden
Background/Purpose: Previous studies have implicated infections as a risk factor for giant cell arteritis (GCA). The purpose of this study was to investigate the association…
Abstract Number: 772 • 2018 ACR/ARHP Annual Meeting
Cytomegaloviral or Pneumocystis Jiroveci Pneumonia Increases Mortality Rate in Systemic Lupus Erythematosus Patients with Pulmonary Hemorrhage: Evidence from Bronchoalveolar Lavage Fluid Analysis
Chien-Chih Lai, Yi-Syuan Sun and De-Feng Huang, Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taiwan, Taipei City, Taiwan
Background/Purpose: To evaluate the role of cytomegaloviral or Pneumocystic jiroveci pneumonia (CMV/PJP) in SLE patients with pulmonary hemorrhage (PH).Methods: We retrospectively examined hospital records for…
Abstract Number: 2142 • 2018 ACR/ARHP Annual Meeting
Exposure to Disease Modifying Antirheumatic Drugs during Pregnancy in Women with Inflammatory Arthritis and the Risk of Serious Maternal Infection: A Population-Based Cohort Study
Mary A. De Vera^1,2,3, Nicole W. Tsao^1,2,3, Eric C. Sayre² and Alyssa Howren^1,2,3, ¹Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³Collaboration for Outcomes Research and Evaluation (CORE), Vancouver, BC, Canada
Background/Purpose: Infection risk is one of the concerns regarding therapy with conventional disease modifying antirheumatic drugs (csDMARDs) and to our knowledge no research has examined…
Abstract Number: 784 • 2018 ACR/ARHP Annual Meeting
Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE
Pablo Castaño-Gonzalez¹, Mauricio Restrepo-Escobar^1,2, Laura Morales-Maya¹, Tomás Urrego¹, Simon Sandoval-Alvares¹, Carlos Horacio Muñoz^1,3, Adriana L Vanegas^1,3, Daniel Jaramillo^1,4, Gloria Vasquez¹ and Luis Gonzalez-Naranjo¹, ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellin, Colombia, ²Hospital Universitario Pablo Tobon Uribe, Medellin, Colombia, ³Hospital Universitario de San Vicente Fundación, Medellín, Colombia, ⁴Hospital Universitario de San Vicente Fundación, Medellin, Colombia
Background/Purpose: Patients with SLE have an increased risk of serious infections, including nosocomial infections, which are associated with potentially modifiable adverse outcomes. Our objective is…
Abstract Number: 2450 • 2018 ACR/ARHP Annual Meeting
Prosthetic Joint Infection in Patients with Rheumatoid Arthritis
John Fredy Jaramillo Gallego¹, Aurelia Luissi¹, Marina Scolnik², Javier Rosa¹ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Patients with rheumatoid arthritis (RA) have been shown to have an increased susceptibility to the development of prosthetic joint infection (PJI) after Total Hip…
Abstract Number: 541 • 2017 ACR/ARHP Annual Meeting
Decreasing Trend of Serious Infections Incidence Rate Along Years in Rheumatoid Arthritis Patients Exposed to Biologics. Data from Two Latin America Registries
Roberto Ranza¹, Ieda Maria Magalhães Laurindo², Georges Christopoulos², Gimena Gomez³, Enrique R Soriano⁴, Miguel Angel Descalzo⁵ and Maria de la Vega⁶, ¹on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, Uberlandia, Brazil, ²on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, São Paulo, Brazil, ³on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos Aires, Argentina, ⁴Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Research Unit, Fundacion piel sana AEDV, Madrid, Spain, Madrid, Spain, ⁶on behalf of BiobadaSar study group, Sociedad Argentina de Reumatologia, Buenos aires, Argentina
Background/Purpose: Infections are the most frequent and concerning serious adverse events related to rheumatoid arthritis (RA) treatment with biologic drugs (bDMARDs). Their safety profile might…
Abstract Number: 2606 • 2017 ACR/ARHP Annual Meeting
Pneumococcal Vaccination in Patients with Systemic Lupus Erythematosus: A Multicenter Placebo-Controlled Randomized Double-Blind Study
Sophie Grabar¹, Matthieu Groh², Mathilde Bahuaud³, Nathalie Costedoat-Chalumeau⁴, Veronique Le Guern⁵, Renato Fior⁶, Boris Bienvenu⁷, eric hachulla⁸, Mohamed Hamidou⁹, Jean Sibilia¹⁰, Alexis Mathian¹¹, Thomas Hanslik¹², Loïc Guillevin for the French Vasculitis Study Group¹³, Frédéric Batteux³ and Odile Launay¹⁴, ¹Université Paris Descartes, Sorbonne Paris Cité AP-HP, Unité de Biostatistique et Epidémiologie, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France; INSERM, UPMC Université Paris 06, Institut Pierre Louis d’épidémiologie et de Santé Publique (IP, Paris, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Université Paris Descartes, Sorbonne Paris Cité AP-HP, Département d’Immunologie Biologique, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Paris, France, Paris, France, ⁴Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁵Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁶Université Paris-Sud, AP-HP, Service de Médecine Interne et Immunologie Clinique, Hôpital Antoine Béclère, Clamart, France, Clamant, France, ⁷Internal Medicine, Hôpital de la côte de Nacre, Caen, France, ⁸chru lille hospital, lille, France, ⁹Medecine Interne, CHU Hôtel Dieu, Nantes, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Université Pierre et Marie Curie, Sorbonne Paris Cité AP-HP, Service de Médecine Interne 2, Centre de Référence National pour le Lupus et le Syndrome des Antiphospholipides, institut E3M, Paris, France, Paris, France, ¹²Université Versailles Saint-Quentin-en-Yvelines, APHP, Service de Médecine Interne, Hôpital Ambroise Paré, Boulogne-Billancourt, France, Boulogne-Billancourt, France, ¹³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ¹⁴Université Paris Descartes, Sorbonne Paris Cité AP-HP, Groupe Hospitalier Cochin Broca Hôtel-Dieu, Fédération d'Infectiologie, Paris, France; Inserm, F-CRIN I-REIVAC., Paris, France
Background/Purpose: Invasive pneumococcal disease and respiratory tract infections are both frequent and severe in patients with systemic lupus erythematosus (SLE). This study aimed to compare…
Abstract Number: 547 • 2017 ACR/ARHP Annual Meeting
Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Diederik De Cock¹, Lianne Kearsley-Fleet¹, Lucía Silva Fernández², Mark Lunt¹, Kath Watson¹, Deborah P.M. Symmons^1,3 and Kimme L. Hyrich^1,3, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In the United Kingdom (UK), rituximab (RTX) or a second tumour necrosis factor inhibitor (TNFi) are both permitted treatment options for patients with rheumatoid…
Abstract Number: 2738 • 2017 ACR/ARHP Annual Meeting
Infectious Complications in Systemic Necrotizing Vasculitides: Pooled Analysis of Five Prospective, Randomized, Controlled Trials
Lafarge Antoine¹, Christian Pagnoux², Xavier Puéchal³, Maxime Samson⁴, Mohamed Hamidou⁵, Alexandre Karras⁶, Thomas Quémeneur⁷, Matthieu Groh⁸, Luc Mouthon⁹, Loïc Guillevin for the French Vasculitis Study Group³ and Benjamin Terrier¹⁰, ¹Medecine Interne, Hôpital Cochin, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Medecine Interne, CHU Hôtel Dieu, Nantes, France, ⁶nephrology, HEGP, Paris, France, ⁷Service de néphrologie, médecine interne et vasculaire, Hôpital de Valenciennes, Valenciennes, France, ⁸National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁹Université Paris Descartes Sorbonne Paris, Paris, France, ¹⁰Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: Prognosis of patients with systemic necrotizing vasculitides has been markedly improved during the last 2 decades. However, infectious complications remain a major cause of…
Abstract Number: 697 • 2017 ACR/ARHP Annual Meeting
Does Erythrocyte Sedimentation Rate Reflect and Discriminate Flare from Infection in Systemic Lupus Erythematosus? Correlation with Clinical and Laboratory Parameters of Disease Activity
Valentin S. Schäfer¹, Katharina Weiss², Andreas Krause² and Wolfgang A. Schmidt³, ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Centre for Rheumatology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ³Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: ESR is applied for monitoring disease activity in SLE. It is known to be influenced by age and infections. We aimed at evaluating how…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].